Skip to main content

Advertisement

Table 2 Comparison of variables between baseline and 6 months after the administration of dapagliflozin

From: Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

  Baseline 6 months p value
Clinical characteristics
 Body weight, kg 66.5 (56.8–76.9) 63.9 (56.2–75.6) < 0.001
 BSA, m2 1.73 (1.57–1.90) 1.72 (1.55–1.88) < 0.001
 Systolic blood pressure, mmHg 130 ± 16 128 ± 18 0.218
 Heart rate, bpm 71 ± 12 70 ± 11 0.610
 BNP, pg/mL 27.9 (9.0–58.2) 28.9 (9.6–62.9) 0.132
 BUN, mg/dL 14.7 (12.1–19.0) 17.2 (14.2–21.2) < 0.001
 Creatinine, mg/dL 0.80 ± 0.20 0.86 ± 0.23 < 0.001
 eGFR, mL/min/1.73 m2 70.6 ± 17.0 65.6 ± 15.3 0.001
 HbA1c, % 7.2 ± 0.8 7.0 ± 0.8 0.108
 Hemoglobin, g/dL 13.7 ± 1.7 14.4 ± 1.6 0.020
 Hematocrit, % 41.0 ± 4.7 43.8 ± 4.5 0.002
 Lipid profiles, mg/dL
  Triglycerides 127 (84–185) 116 (82–176) 0.155
  LDL cholesterol 98 (86–118) 106 (89–126) 0.078
  HDL cholesterol 51.5 (45.0–60.2) 52 (42.8–65.0) 0.049
 Uric acid, mg/dL 5.1 (4.4–5.9) 4.7 (4.2–5.7) 0.057
Echocardiographic parameters
 LV end-diastolic volume, mL 74.2 (55.1–104.1) 68.5 (54.8–93.8) 0.270
 LV end-systolic volume, mL 24.7 (17.0–54.5) 20.5 (15.2–57.1) 0.105
 LVEF, % 62.3 (49.3–68.3) 63.6 (55.3–71.0) 0.011
 LVMI, g/m2 75.0 (61.7–92.0) 67.0 (55.0–81.9) < 0.001
 LAVI, mL/m2 31 (23–45) 26 (21–32) 0.001
 e′, cm/s 6.36 ± 1.73 6.82 ± 1.88 0.031
 E/e′ 9.3 (7.7–11.8) 8.5 (6.6–10.7) 0.020
 E, cm/s 58.1 (46.8–70.9) 55.1 (45.3–73.7) 0.682
 A, cm/s 76.1 ± 17.8 75.6 ± 16.8 0.765
 E/A 0.71 (0.6–0.80) 0.70 (0.62–0.81) 0.818
  1. Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
  2. Abbreviation as in Table 1